Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504425 | 1.00 | PTGES (0.44) | PTGESMAOAMAOBCASP3FFAR1 | |
| SCHEMBL31504440 | 0.93 | PTGES (0.45) | PTGESMAOAMAOBCTSVCTSL | |
| SCHEMBL21617212 | 0.93 | PTGES (0.45) | PTGESMAOAMAOBCTSVCTSL | |
| SCHEMBL21617219 | 0.90 | PTGES (0.43) | PTGESMAOAMAOBCASP3CTSV | |
| SCHEMBL31504380 | 0.90 | PTGES (0.43) | PTGESMAOAMAOBCASP3CTSV | |
| SCHEMBL21617288 | 0.88 | PTGES (0.41) | PTGESMAOAMAOBACACBS1PR1 | |
| SCHEMBL21623514 | 0.88 | MAOA (0.42) | PTGESMAOAMAOBS1PR1S1PR5 | |
| SCHEMBL31504402 | 0.88 | PTGES (0.41) | PTGESMAOAMAOBACACBS1PR1 | |
| SCHEMBL23308016 | 0.76 | CNR2 (0.42) | GPR132 | |
| SCHEMBL23308005 | 0.75 | ALDH1A1 (0.45) | MAOBCTSVCTSLSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820850-B1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-09-23 | — | — | US | disclosed |
| EP-3820850-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | NSUN3, CBR3, C1R | PTGES 3685/4885MAOA 1648/4885MAOB 2297/4885 |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | NSUN3, CBR3, C1R | PTGES 3685/4885MAOA 1648/4885MAOB 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.